Sunscreen Drug Products for Over-the-Counter Human Use
FDA proposes final monograph for OTC sunscreen drug products, affecting cosmetics and personal care businesses under MoCRA.
Aforeworn detected this change in the Cosmetics & Personal-Care (MoCRA) space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Indie beauty brands, contract manufacturers, private-label makers, importers/distributors of sunscreen products should confirm how it applies to their specific situation before acting. There is a time constraint attached: Comment period ends 60 days after publication (likely April 2019); final rule effective date TBD.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Cosmetics & Personal-Care (MoCRA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA is proposing to finalize conditions for OTC sunscreen drug products, including active ingredient safety, labeling, and testing requirements.
Who it affects
Indie beauty brands, contract manufacturers, private-label makers, importers/distributors of sunscreen products
What you must do
Review proposed rule and prepare for compliance with new monograph requirements once finalized.
Deadline
Comment period ends 60 days after publication (likely April 2019); final rule effective date TBD.
Never miss a change like this again
Aforeworn watches Cosmetics & Personal-Care (MoCRA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Cosmetics & Personal-Care (MoCRA)
- FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight
- FDA Grants Seventh Approval under the National Priority Voucher Pilot Program
- FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics
- FDA Expands AI Capabilities and Completes Data Platform Consolidation
- FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection